tress and defects of the kidneys, liver, heart, and brain. 18 Even long-term survivors can have abnormalities later in life. Aging cloned mice were recently reported to become obese, 19 die prematurely, and have tumors. 20 Some of these phenotypes do, however, appear to be specific to the type of donor cell used. For example, clones derived from cumulus cells (somatic cells that surround the egg) become obese, 19 whereas clones derived from Sertoli cells (somatic cells that nourish the egg) die prematurely. 20 However, these abnormalities are not inherited by the offspring of the clones, suggesting that epigenetic rather than genetic aberrations are the cause; epigenetic changes, in contrast to genetic changes, are reversible modifications of DNA or chromatin that are usually erased in the germ line. These results indicate that most problems associated with cloning appear to be due to faulty epigenetic reprogramming of the transplanted nucleus.
faulty epigenetic reprogramming in clones
Faulty epigenetic reprogramming is the failure to return the gene-expression program of a somatic donor nucleus to an embryonic pattern of expression. 2 At the molecular level, epigenetic modifications that are specific to the differentiated cell, such as DNA methylation, histone modifications, and the overall chromatin structure, need to be reprogrammed to a state compatible with embryonic development. Consistent with this notion is the finding that embryos cloned from somatic cells frequently fail to reactivate key embryonic genes at the blastocyst stage. 21, 22 Moreover, cloned embryos can have aberrant patterns of DNA methylation [23] [24] [25] and precocious expression of genes specific to the donor cell. 26 In contrast, embryos cloned from embryonic stem cells faithfully express early embryonic genes, 21 possibly because these genes are already active in the donor genome. This might explain why cloning from embryonic stem cells is roughly 10 to 20 times as efficient as cloning from somatic cells (Table 1) .
During normal development, reprogramming occurs before and after the formation of the zygote 2,27 (Table 2) . Faithful reprogramming ensures the proper activation of genes during embryonic development. Prezygotic reprogramming includes the * Shown is a comparison of preimplantation ("zygote into blastocyst") and postimplantation ("blastocyst into mouse") development of clones derived from different donor cells. The use of embryonic cells (blastomere cells and embryonic stem cells) leads to a higher rate of postimplantation development of cloned embryos than does the use of adult donor cells (fibroblasts and cumulus cells). Therapeutic cloning ("blastocyst into embryonic stem cells") is more efficient than reproductive cloning ("blastocyst into mouse"). Regardless of the type of donor cell used, cloned animals have common abnormalities. † No live cloned mice have been derived from lymphocytes by direct embryo transfer. 4 However, monoclonal mice have been generated by a modified, two-step cloning procedure. 5 ‡ Abnormalities include an unusually large fetus and placenta, respiratory distress, and defects of the kidneys, liver, heart, and brain. acquisition of genomic imprints -the expression of genes from either the paternal or maternal set of chromosomes -as well as the modification of most somatic genes during gametogenesis. Inactivation of the X chromosome and adjustment of the length of telomeres are examples of postzygotic reprogramming.
prezygotic reprogramming
Because cloning uses an unfertilized, mature oocyte, reprogramming has to occur within the brief interval between the transfer of the donor nucleus into the oocyte and the start of zygotic transcription. Thus, prezygotic modifications (i.e., any modifications that have occurred before the mature oocyte stage) are expected to be less efficiently reprogrammed than postzygotic modifications. Consistent with this hypothesis is the fact that aberrant imprints in donor nuclei are usually not corrected in the clones. Genomic imprinting is an epigenetic modification of DNA resulting in the monoallelic and parent-of-origin-specific expression of certain genes. The dysregulation of imprinted genes is particularly pronounced in cloned mice derived from embryonic stem cells, because cultured embryonic stem cells are epigenetically very unstable and frequently gain or lose genomic imprints. 16 Cloned mice derived from uncultured cumulus cells with normal imprints also have aberrant expression of imprinted genes, 28 suggesting that the dysregulation of imprinted genes is influenced by both the epigenetic state of the donor cell and the nuclear-transfer procedure. Since imprinted genes are important for fetal growth and placental function, aberrant expression of these genes might account for the severely abnormal fetal and placental phenotypes in many clones.
To assess the degree of dysregulation of nonimprinted genes, gene-expression analyses have been performed on newborn clones. These analyses revealed that hundreds of genes are aberrantly expressed in the placentas and livers of cloned mice derived from either cumulus or embryonic stem cells 28 (Table 2) . Interestingly, a subgroup of these genes was found to be misexpressed exclusively in clones derived from cumulus cells, and another subgroup was aberrantly expressed only in clones derived from embryonic stem cells -a result consistent with the finding that clones derived from different types of donor cells can have different abnormalities. 3,19,20 Therefore, prezygotic reprogramming, which affects the expression of imprinted and most nonimprinted genes, appears to be faulty in clones.
postzygotic reprogramming
Telomeres are structures that protect the ends of chromosomes. Telomeres progressively shorten with each cell division, and this shortening has been correlated with cellular and organismal aging. In most cloned animals, the lengths of telomeres are normal or even longer than normal, [30] [31] [32] [33] suggest-* During normal development, epigenetic reprogramming occurs before and after the formation of the zygote to ensure activation of the proper genes in the developing embryo. During clonal development, reprogramming is limited to the short interval between the transfer of the nucleus into the mature oocyte and the activation of embryonic transcription. Consequently, prezygotic modifications of imprinted and nonimprinted genes are less efficiently reprogrammed in clones than are postzygotic modifications, such as inactivation of the X chromosome and adjustment of the length of telomeres. Data were adapted from Jaenisch et al. 27 with the permission of the publisher; gene expression of imprinted and nonimprinted genes was analyzed with use of 11K Affymetrix gene chips. Humpherys et al. 16 After the zygote is formed X inactivation
Adjustment of telomere length
Same as in normal embryos (random in the mouse) Same as in normal embryos (ends are normal or longer)
Eggan et al. 29 Betts et al., 30 Lanza et al., 31 Tian et al., 32 and Wakayama et al. 33 ing that cloned embryos faithfully restore telomere length to that of normal embryos ( Table 2) . Inactivation of one X chromosome in female cells is a mechanism that ensures equal dosage of X-linked genes in the two sexes. It is accomplished by the random and stable silencing of one of the two X chromosomes early in embryogenesis. In embryos cloned from female somatic cells, the inactive X was found to be reactivated properly, resulting in random X inactivation in the mouse 29 (Table 2) . Thus, most postzygotic modifications appear to be properly reprogrammed in clones and are therefore not expected to impede the development of clones.
In summary, all available evidence indicates that reproductive cloning, in contrast to normal development or in vitro fertilization, is limited by the fundamental biologic problem of epigenetic reprogramming of the donor nucleus. Specifically, prezygotic modifications that usually occur during gametogenesis are not corrected in the clones. This incomplete reprogramming may result in abnormal phenotypes, aberrant gene expression, and the death of most clones. Consequently, even the rare surviving clones are likely to have at least subtle abnormalities.
differentiation and cloning efficiency
The efficiency of obtaining cloned animals from adult donor cells is low in most species. In general, 1 to 3 percent of cloned blastocysts develop completely 1,2,7,8 (Table 1 ). This rate is slightly higher in cows, in which up to 10 percent of cloned embryos develop to term. 34 In contrast to the results of cloning involving somatic donor cells, the results of cloning involving embryonic cells such as blastomeres (cells of the cleavage embryo) or embryonic stem cells are more efficient (10 to 30 percent of cloned blastocysts develop successfully) 3,10-12 (Table 1), suggesting that the state of differentiation of the donor cell directly affects the efficiency of cloning. This observation is consistent with the idea that embryonic cells require less reprogramming of their genome, because the genes essential for early embryonic development are already active. In fact, the transfer of the nucleus of an embryonic cell, such as an embryonic stem cell, might have nearly the same rate of success in generating live-born mice as does transfer of the zygotic nucleus (or pronucleus) 13 (Table 1) . However, mice cloned from the nuclei of embryonic stem cells, in contrast to mice derived from zygotic nuclei, are abnormal, 10 indicating that gametogenesis and fertilization endow zygotic nuclei with the ability to direct normal development. In summary, these data indicate that cells progressively lose nuclear potency as they develop.
terminally differentiated cells remain totipotent
The loss of nuclear potency in differentiating cells raised the important question of whether the nuclei of terminally differentiated donor cells retain developmental totipotency -that is, the potential to give rise to an entire organism. Previous nucleartransfer experiments in frogs 35 and mammals 36 failed to resolve this question, because of the lack of appropriate genetic markers that would unambiguously identify terminally differentiated cells within a heterogeneous population of donor cells. It is possible that the clones were not derived from differentiated donor cells but rather from adult stem cells that were present in the adult donor animal at low frequencies. 3, [37] [38] [39] To address this question, we created monoclonal mice from terminally differentiated lymphocytes. 5 The characteristic genetic rearrangements at the immune-receptor loci of mature lymphoid cells served as genetic markers, which allowed us to draw the retrospective and unambiguous conclusion that the clones had been derived from a terminally differentiated donor nucleus. We found that nuclei from mature B and T cells were able to direct development after being transferred into an oocyte, but this process was much less efficient than cloning involving other adult donor cells, such as fibroblasts or cumulus cells 6-8 (Table 1) . Previous attempts to generate monoclonal mice from lymphoid donor nuclei by the direct transfer of blastocysts into the uterus were unsuccessful. 4 To derive monoclonal mice from the nuclei of mature B and T cells, we used a two-step cloning procedure in which the derivation of embryonic stem cells from cloned blastocysts was followed by tetraploid embryo complementation. 10 In this approach, diploid embryonic stem cells are injected into tetraploid host blastocysts to generate mice. Because tetraploid cells can form a functional placenta but not an embryo, the resultant mice had to have been derived entirely from the injected embryonic stem cells.
Although the generation of monoclonal mice demonstrated unequivocally that terminally differentiated cells can remain genetically totipotent, these results did not exclude the possibility that many cloned animals are derived from less well dif-ferentiated adult cells, such as adult stem cells. The genome of adult stem cells might resemble that of embryonic stem cells, which is more amenable to or requires less reprogramming than the genome of a differentiated cell. It will be interesting to test whether purified adult stem cells can serve as efficient somatic donor cells. This question is also of importance with respect to the potential therapeutic application of nuclear transfer; because nuclear transfer is inherently inefficient, it will be essential to identify the most efficient donor cell in the adult in order to reduce the number of oocytes that are needed to establish a line of embryonic stem cells.
reproductive cloning versus therapeutic cloning
In addition to its value in the study of nuclear changes during differentiation, nuclear-transfer technology has substantial therapeutic potential. For the following discussion, it is important to distinguish between reproductive cloning and nuclear-transplantation therapy (also referred to as therapeutic cloning) 40, 41 (Fig. 1) . The purpose of reproductive cloning is to generate a cloned embryo, which is then implanted in the uterus of a female to give rise to a cloned individual. In contrast, the purpose of nuclear-transplantation therapy is to generate an autologous embryonic stem-cell line that is derived from a cloned embryo -referred to as nucleartransfer embryonic stem cells -and that can be used for tissue replacement.
Rejection is a frequent complication of allogeneic organ transplantation, owing to immunologic incompatibility. To prevent this host-versus-graft disease, immunosuppressive drugs are routinely given to transplant recipients -a treatment that has serious side effects. Embryonic stem cells derived from nuclear transplantation are genetically identical to the patient's cells, thus eliminating the risk of immune rejection and the requirement for immunosuppression. Moreover, embryonic stem cells provide a renewable source of replacement tissue, allowing therapy to be repeated whenever needed.
differentiation into functional cells
Therapeutic cloning requires the in vitro differentiation of nuclear-transfer embryonic stem cells into a homogeneous population of functional cells that can be used for cell therapy. In some circumstances, these cells may first need to be manipulated to correct defects. Recently, protocols have been developed that allow homologous recombination and thus genetic manipulation of human embryonic stem cells. 42 Various studies have described the potential of human embryonic stem cells to differentiate into multiple lineages, 43, 44 such as neural progenitors, [45] [46] [47] hematopoietic precursors, 48 and insulin-secreting cells. 49 Protocols for the differentiation of murine embryonic stem cells into functional cells of many if not all organs present in adult mice are well established (Table 3 ). For example, embryonic stem cells can generate functional motor neurons when they are exposed to signals that normally induce neurogenesis. 50 With a different strategy, drug-selection protocols have been used to cause embryonic stem cells to differentiate into homogeneous populations of cardiomyocytes, 54 neuroepithelial precursor cells, 55 and insulin-producing cells. 52 The expression of the homeobox protein HoxB4 in embryoid bodies generates hematopoietic stem cells that avert death in mice that have received lethal doses of radiation. 53 Similarly, the expression of nuclear receptor-related factor 1 (Nurr1), an orphan nuclear receptor that is expressed chiefly in the central nervous system, in embryonic stem cells induces the formation of dopaminergic neurons that can relieve behavioral symptoms in rats with Parkinson's disease. 51
combining nuclear cloning with gene and cell therapy
The ultimate goal of therapeutic cloning is to generate functional cells from cloned embryonic stem cells that can be used for cell transplantation in patients. Several groups, including ours, have shown that nuclear-transfer embryonic stem cells can be derived from mouse cumulus or fibroblast cells and that these cells can be coaxed into becoming somatic cells such as myogenic cells, dopaminergic and serotonergic neurons, or hematopoietic cells. 5,6,9,56 However, before these principles can be applied clinically, it is important to demonstrate the feasibility of therapeutic cloning in an animal model of disease.
In an attempt to establish such a mouse model, we have combined nuclear cloning with gene and cell therapy to treat a genetic disorder (Fig. 2) . 56 We chose the well-characterized Rag2 mutant mouse, which has severe combined immunodeficiency owtherapeutic potential of nuclear transplantation ing to a mutation in the recombination-activating gene 2 ( Rag2 ), which catalyzes immune-receptor rearrangements in lymphocytes. This mouse is devoid of mature B and T cells, a condition resembling Omenn's syndrome in humans. First, we isolated somatic (fibroblast) cells from the tails of Rag2 -deficient mice and injected the nuclei of these cells into enucleated eggs. We then cultured the resultant embryos to the blastocyst stage and isolated the autologous embryonic stem cells. Subsequently, one of the mutant Rag2 alleles was targeted by homologous recombination in embryonic stem cells in order to restore normal gene structure. To obtain somatic cells for treatment, these embryonic stem cells underwent differentiation into embryoid bodies (embryo-like structures that contain various types of somatic cells) and further into hematopoietic precursors by expressing HoxB4. The resulting hema- During normal development (Panel A), a haploid (1n) sperm cell fertilizes a haploid oocyte to form a diploid (2n) zygote that undergoes cleavage to become a blastocyst embryo. Blastocysts are implanted in the uterus and ultimately give rise to an animal. During reproductive cloning (Panel B), the diploid nucleus of an adult donor cell is introduced into an enucleated oocyte, which after artificial activation divides into a cloned blastocyst. On transfer into surrogate mothers, a few of the cloned blastocysts will give rise to a clone. In contrast, therapeutic cloning (Panel C) requires the explantation of cloned blastocysts in culture to yield a line of embryonic stem cells that can potentially differentiate in vitro into any type of cell for therapeutic purposes. topoietic precursors were transplanted into irradiated Rag2 -deficient animals to treat the disease. The initial attempts to engraft these cells were unsuccessful because of an increased level of natural killer cells in the mutant host. Hematopoietic cells derived from embryonic stem cells express low levels of major-histocompatibility-complex class I molecules and are thus a preferred target of destruction by natural killer cells. Elimination of the natural killer cells by antibody depletion or genetic ablation allowed the nuclear-transfer embryonic stem cells to differentiate into the myeloid lineages efficiently and, to a lesser degree, into the lymphoid lineages. Functional B and T cells whose immunoglobulin and T-cell-receptor alleles had been properly rearranged were detected in the mice, as were serum immunoglobulins. However, because HoxB4 appears to promote the differentiation of embryonic stem cells into myeloid cells, lymphoid reconstitution might be more successful if transcription factors specific to the lymphoid lineage were used.
This experiment demonstrated that nuclear transfer can be combined with gene therapy to treat a genetic disorder. Consequently, therapeutic cloning should be useful in other diseases in which the genetic cause is known, such as sickle cell anemia and b -thalassemia.
faulty reprogramming in clones as a potential impediment to therapeutic applications
An important question is whether the reprogramming errors leading to abnormal phenotypes in cloned animals would impede the therapeutic use of nuclear-transfer technology. For the derivation of embryonic stem cells from fertilized embryos, blastocysts are explanted in vitro and cultured until a small colony forms that can be dissociated. Only one or a few of the dissociated cells have the potential to grow into an embryonic stem-cell line, 57 suggesting that competent cells are selected for in culture. Similarly, the derivation of embryonic stem cells from cloned blastocysts may be the result of selection for a few successfully reprogrammed cells within a cloned embryo (Fig. 3) . In contrast, the development of a cloned embryo after implantation most likely does not allow for the in vivo selection of a few functional cells, thus causing developmental failure of the clone or phenotypic abnormalities. In support of this notion, the derivation of embryonic stem cells from somatic donor cells is more efficient 5,6,9,56 than is the generation of cloned mice 4,7,8 (Table 1) .
Abnormal fetal development is the most fundamental cause of clone failure. In contrast to the result of reproductive cloning, no fetus is formed in therapeutic cloning. Thus, aberrant expression of genes that are essential for normal fetal development, such as imprinted genes, is not expected to impede the functionality of embryonic stem cells that undergo differentiation in vitro. The abnormal expression of some imprinted genes, such as the gene for insulin-like growth factor 2, however, has been associated with disease in the adult, 58, 59 and it will be important to determine whether dysregulation of these genes has adverse effects on the function of somatic cells derived from embryonic stem cells.
Nuclear-transfer embryonic stem cells have the same developmental potency as embryonic stem limitations and alternatives cells derived from fertilized eggs. When injected into blastocysts, nuclear-transfer embryonic stem cells contributed to tissues of all three germ layers, including the germ line. 6 A subgroup of these embryonic stem-cell lines was even able to produce mice after tetraploid embryo complementation, 5,56 a process that allows the generation of mice from embryonic stem cells alone. It is notable that the abnormalities regularly associated with cloned animals were not observed in these mice. In any therapeutic setting, cells derived from nuclear-transfer embryonic stem cells will be introduced into a patient with a disease, and host cells will interact with the transplanted cloned cells to generate a chimeric tissue. Chimeric animals generated by the injection of normal or nuclear-trans- Tail-tip cells were obtained from mice with a deficiency of recombination-activating gene 2 ( Rag2 ) and cultured, and the nuclei were transferred into enucleated oocytes. The cloned embryos were cultured to the blastocyst stage to derive autologous embryonic stem cells. After one of the mutant Rag2 alleles was repaired by homologous recombination, embryonic stem cells were induced to differentiate into embryoid bodies (embryo-like structures that contain various types of somatic cells) and infected with a retrovirus expressing the homeobox protein HoxB4. The resultant hematopoietic stem cells were clonally expanded and injected intravenously into irradiated Rag2 -deficient animals to reconstitute their immune system. Adapted from Rideout et al., 56 with the permission of the publisher. Expand hematopoietic stem cells in culture and transplant into Rag2-deficient mouse fer embryonic stem cells into normal blastocysts form normal chimeras. 6,9 This finding suggests that the presence of host helper cells, which are derived from the fertilized egg, complement the defects that invariably result when a cloned animal is generated from a somatic or embryonic donor nucleus. In support of this notion, Byrne et al. showed that embryonic cells derived from nuclear transfer failed to develop on their own in frogs but integrated normally when they were combined with wildtype embryos to form chimeric tadpoles. 60 In summary, these considerations suggest that nucleartransfer embryonic stem cells are equivalent to embryonic stem cells derived from a fertilized zygote. Only a few of the cells of a blastocyst derived from a fertilized zygote have the potential to produce an embryonic stem-cell line, and these cells seem to be selected for by culture conditions (top panel). Mice derived from fertilized zygotes are normal because the sperm and oocyte genomes have undergone proper reprogramming during gametogenesis (top panel). However, cloned blastocysts and the resultant mice seem to maintain a memory of the epigenetic state of the donor nucleus they were derived from (bottom panel). This is probably due to faulty reprogramming of the somatic donor nucleus after nuclear transfer and results in abnormal phenotypes and aberrant patterns of gene expression. These epigenetic abnormalities are represented by the pink halo surrounding the cloned embryo and mouse. In contrast, the derivation of embryonic stem cells from cloned blastocysts appears to select for fully reprogrammed, functional cells that have lost this epigenetic memory. The therapeutic potential of adult stem cells appears to be much lower than that of embryonic stem cells. First, adult stem cells are difficult to isolate and hard to propagate in culture. In contrast, embryonic stem cells are derived rather easily (once an embryo has been obtained), and they grow indefinitely in culture. Second, embryonic stem cells can be manipulated genetically by homologous recombination to correct a genetic defect. 56 In contrast, currently, adult stem cells can be genetically manipulated only through the introduction of retroviral transgenes, which overexpress genes at variable levels and can lead to insertional mutagenesis and cancer. 68 Third, embryonic stem cells can be coaxed into becoming any type of cell through the use of specific culture conditions or genetic manipulation. The differentiation potential of adult stem cells, however, seems to be restricted.
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One notable exception in this respect is the recent isolation of multipotent adult progenitor cells. 69 Multipotent adult progenitor cells were derived from the bone marrow of adult mice, rats, and humans after a three-month culture protocol. These cells have the potential to differentiate into cells of all three germ layers both in vitro and in vivo after being injected into blastocysts. However, it has not been demonstrated in animal models or humans that multipotent adult progenitor cells can be used to correct a disease phenotype.
the requirement for human oocytes
To overcome the ethical and practical limitations of therapeutic cloning, it would be useful to reprogram somatic cells directly into embryonic stem cells without the use of oocytes. An understanding of the factors that have a role in establishing and maintaining pluripotency might make it possible to alter the fate of somatic cells directly. For instance, the embryonic transcription factor Oct-4 appears to act as a regulator of pluripotency during development. 57, 70 When mutated, embryos cannot form a pluripotent inner cell mass, and their development is arrested. 71 Thus, manipulation of Oct-4 and related genes 21 in somatic cells might help to reprogram their nuclei to an embryonic state. This could reduce or even circumvent the need for human oocytes.
Recently, Hübner et al. provided evidence of the differentiation of murine embryonic stem cells into oocyte-like cells in vitro. 72 It will be interesting to determine whether oocytes can be obtained from human embryonic stem cells and whether these cells are suitable for nuclear transfer.
Therapeutic cloning, in combination with the differentiation potential of embryonic stem cells, offers a valuable means of obtaining autologous cells for the treatment of a variety of diseases. The abnormalities associated with reproductive cloning are not expected to impede the use of this technique for therapy, since the process seems to select for functional cells. However, before these principles can be applied clinically, it will be essential to improve differentiation protocols for human embryonic stem cells and to evaluate the effect of oocytederived mitochondrial proteins in somatic cells obtained by nuclear transfer. In the future it might be possible to generate embryonic stem cells directly from somatic cells. It is important, therefore, to continue research aimed at improving our understanding of the molecular events that take place during nuclear reprogramming, in order to develop these potential new therapies.
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